Author

D. Sasca

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:chromatin & epigenetic regulation· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

G. Giotopoulos· 3 shared H. Yun· 3 shared S. J. Horton· 3 shared B. J. P. Huntly· 2 shared E. Meduri· 2 shared F. Basheer· 2 shared P. Gallipoli· 2 shared S. Agrawal-Singh· 2 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

G. Giotopoulos

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

HOXA9 forms a repressive complex with nuclear matrix-associated protein SAFB to maintain acute myeloid leukemia

S. Agrawal Singh, J. Bagri, G. Giotopoulos, D. Azazi, S. J. Horton, J. W. Houghton, S. Anand, A. S. Bach, F. Stedham, R. Antrobus, G. Vassiliou, D. Sasca, H. Yun, A. Whetton, B. J. P. Huntly

This study identifies a repressive HOXA9-SAFB complex in AML that maintains disease by inhibiting differentiation and apoptosis, suggesting therapeutic targets.

bioRxiv · Oct 12, 2022 · PreprintCancer Biology

Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 co-activation

V. Shah, G. Giotopoulos, H. Osaki, M. Meyerhoefer, E. Meduri, B. Schubert, H. Yun, S. J. Horton, S. Agrawal-Singh, P. S. Haehnel, F. Basheer, D. Lugo, M. W. Kuehn, B. Guezguez, M. Theobald, , D. Sasca

This study identifies p300-mediated compensatory transcriptional programs that drive acute resistance to BET inhibitors in AML and suggests sequential BET- and p300-inhibition as a therapeutic strategy.

bioRxiv · Sep 14, 2022 · PreprintCancer Biology

Mutational synergy coordinately remodels chromatin accessibility, enhancer landscape and 3-Dimensional DNA topology to alter gene expression during leukemia induction

H. Yun, S. Vohra, A. Mupo, G. Giotopoulos, D. Sasca, S. J. Horton, S. Agrawal-Singh, E. Meduri, F. Basheer, L. Marando, M. Gozdecka, O. M. Dovey, A. Castillo-Venzor, X. Wang, P. Gallipoli, , B. J. P. Huntly

The paper investigates how mutations synergize to alter chromatin accessibility, enhancer landscapes, and 3D DNA topology in leukemia induction using a murine model.

bioRxiv · Mar 20, 2020Cancer Biology